Alternative splicing within the human cytochrome P450 superfamily with an emphasis on the brain: The convolution continues

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 3, 2006, Pages 399-418

  Turman, Cheri M ^a   Hatley, Jade M ^a   Ryder, Daniel J ^a   Ravindranath, Vijayalakshmi ^b   Strobel, Henry W ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b NATIONAL BRAIN RESEARCH CENTRE   (India)

Author keywords

Alternative splicing; Brain CYPs; Cytochrome P450; Drug metabolism

Indexed keywords

CYTOCHROME P450; PSYCHOTROPIC AGENT;

ALTERNATIVE RNA SPLICING; COMPUTER AIDED DESIGN; DRUG DESIGN; GENE CONTROL; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; MICROARRAY ANALYSIS; PROTEIN FAMILY; REVIEW; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION;

ALTERNATIVE SPLICING; ANIMALS; BRAIN; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; ISOENZYMES; LIVER; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33846449521     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.3.399     Document Type: Review

References (105)

1. CUI X, KALSOTRA A, ROBIDA AM et al.: Expression of cytochromes P450 4F4 and 4F5 in infection and injury models of inflammation. Biochim. Biophys. Acta (2003) 1619(3):325-331.
2. KALSOTRA A, CUI X, ANTONOVIC L et al.: Inflammatory prompts produce isoform-specific changes in the expression of leukotriene B(4) ζ-hydroxylases in rat liver and kidney. FEBS Lett. (2003) 555(2):236-242.
3. MICHELS R, MARZUK PM: Progress in psychiatry (2). N. Engl. J. Med. (1993) 329(9):628-638. Review of psychopharmacotherapy.
4. MICHELS R, MARZUK PM: Progress in psychiatry (1). N. Engl. J. Med. (1993) 329(8):552-560.
5. WILCOX RA, OWEN H: Variable cytochrome P450 2D6 expression and metabolism of codeine and other opioid prodrugs: implications for the Australian anaesthetist. Anaesth. Intensive Care (2000) 28(6):611-619.
6. BROCKMOLLER J, KIRCHHEINER J, MEISEL C, ROOTS I: Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics (2000) 1(2):125-151.
7. DALY AK: Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol. (2003) 17(1):27-41.
8. INGELMAN-SUNDBERG M: Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch. Pharmacol. (2004) 369(1):89-104.
9. GUENGERICH FP, LIEBLER DC: Enzymatic activation of chemicals to toxic metabolites. Crit. Rev. Toxicol. (1985) 14(3):259-307.
10. NATION RL, EVANS AM, MILNE RW: Pharmacokinetic drug interactions with phenytoin (Part I). Clin. Pharmacokinet. (1990) 18(1):37-60.
11. GAD SC: Active drug metabolites in drug development. Curr. Opin. Pharmacol. (2003) 3(1):98-100.
12. NELSON DR, KOYMANS L, KAMATAKI T et al.: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics(1996) 6(1):1-42.
13. ANZENBACHER P, ANZENBACHEROVA E: Cytochromes P450 and metabolism of xenobiotics. Cell. Mol. Life Sci. (2001) 58(5-6):737-747.
14. NELSON DR, ZELDIN DC, HOFFMAN SM et al.: Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics (2004) 14(1):1-18.
15. HUTZLER M, MESSING DM, WIENKERS LC: Predicting drug-drug interactions in drug discovery: where are we now and where are we going? Curr. Opin. Drug Discov. Devel. (2005) 8(1):51-58.
16. TANG C, LIN JH, LU AY: Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction? Drug Metab. Dispos. (2005) 33(5):603-613.
17. OZAWA S, SOYAMA A, SAEKI M et al.: Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab. Pharmacokinet. (2004) 19(2):83-95.
18. ROOTS I, GERLOFF T, MEISEL C et al.: Pharmacogenetics-based new therapeutic concepts. Drug Metab. Rev. (2004) 36(3-4):617-638.
19. EVANS DA, MAHGOUB A, SLOAN TP, IDLE JR, SMITH RL: A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. Med. Genet. (1980) 17(2):102-105.
20. GONZALEZ FJ, SKODA RC, KIMURA S et al.: Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (1988) 331(6155):442-446.
21. CROFT L, SCHANDORFF S, CLARK F et al.: ISIS, the intron information system, reveals the high frequency of alternative splicing in the human genome. Nat. Genet. (2000) 24(4):340-341.
22. SCHMUCKER D, CLEMENS JC, SHU H et al.: Drosophila Dscam is an axon guidance receptor exhibiting extraordinary molecular diversity. Cell (2000) 101(6):671-684.
23. LAREAU LF, GREEN RE, BHATNAGAR RS, BRENNER SE: The evolving roles of alternative splicing. Curr. Opin. Struct. Biol. (2004) 14(3):273-282.
24. ZAPHIROPOULOS PG, FOLK WR, COON MJ: Isolation and characterization of a novel cytochrome P450-like pseudogene. Biochem. Biophys. Res. Commun. (1986) 134(2):499-505.
25. WONG G, KAWAJIRI K, NEGISHI M: Gene family of male-specific testosterone 16 α-hydroxylase (C-P450(16)-α) in mouse liver: cDNA sequences, neonatal imprinting, and reversible regulation by androgen. Biochemistry (1987) 26(26):8683-8690.
26. OKINO ST, QUATTROCHI LC, PENDURTHI UR, MCBRIDE OW, TUKEY RH: Characterization of multiple human cytochrome P450 1 cDNAs. The chromosomal localization of the gene and evidence for alternate RNA splicing. J. Biol. Chem. (1987) 262(33):16072-16079.
27. CHEN W, KUBOTA S, TERAMOTO T et al.: Silent nucleotide substitution in the sterol 27-hydroxylase gene (CYP 27) leads to alternative pre-mRNA splicing by activating a cryptic 5′ splice site at the mutant codon in cerebrotendinous xanthomatosis patients. Biochemistry (1998) 37(13):4420-4428.
28. CHRISTMAS P, JONES JP, PATTEN CJ et al.: Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J. Biol. Chem. (2001) 276(41):38166-38172. Evidence of functional CYP splice variant.
29. PAI HV, KOMMADDI RP, CHINTA SJ et al.: A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502D7 that demethylates codeine to morphine. J. Biol. Chem. (2004) 279(26):27383-27389. Evidence of functional CYP splice variant.
30. BLACK DL: Mechanisms of alternative pre-messenger RNA splicing. Ann. Rev. Biochem. (2003) 72:291-336. Review of alternative splicing.
31. CARTEGNI L, CHEW SL, KRAINER AR: Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. (2002) 3(4):285-298. Review of alternative splicing.
32. KUEHL P, ZHANG J, LIN Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. (2001) 27(4):383-391.
33. VERRIPS A, STEENBERGEN-SPANJERS GC, LUYTEN JA et al.: Exon skipping in the sterol 27-hydroxylase gene leads to cerebrotendinous xanthomatosis. Hum. Genet. (1997) 100(2):284-286.
34. MAAS RM, REUS K, DIESEL B et al.: Amplification and expression of splice variants of the gene encoding the P450 cytochrome 25-hydroxyvitamin D(3) 1,α-hydroxylase (CYP 27B1) in human malignant glioma. Clin. Cancer Res. (2001) 7(4):868-875.
35. CHINTA SJ, KOMMADDI RP, TURMAN CM, STROBEL HW, RAVINDRANATH V: Constitutive expression and localization of cytochrome P450 1A1 in rat and human brain: presence of a splice variant form in human brain. J. Neurochem. (2005) 93(3):724-736.
36. ALLORGE D, CHEVALIER D, LO-GUIDICE JM et al.: Identification of a novel splice-site mutation in the CYP1A2 gene. Br. J. Clin. Pharmacol. (2003) 56(3):341-344.
37. DING S, LAKE BG, FRIEDBERG T, WOLF CR: Expression and alternative splicing of the cytochrome P450 CYP2A7. Biochem. J. (1995) 306(Pt 1):161-166.
38. BLUMENTHAL T: Gene clusters and polycistronic transcription in eukaryotes. Bioessays (1998) 20(6):480-487.
39. FINTA C, WARNER SC, ZAPHIROPOULOS PG: Intergenic mRNAs. Minor gene products or tools of diversity? Histol. Histopathol. (2002) 17(2):677-682. Review of intergenic splicing.
40. FINTA C, ZAPHIROPOULOS PG: The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene (2000) 260(1-2):13-23.
41. RODRIGUEZ-ANTONA C, AXELSON M, OTTER C, RANE A, INGELMAN-SUNDBERG M: A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1. J. Biol. Chem. (2005) 280(31):28324-28331.
42. ZAPHIROPOULOS PG: RNA molecules containing exons originating from different members of the cytochrome P450 2C gene subfamily (CYP2C) in human epidermis and liver. Nucleic Acids Res. (1999) 27(13):2585-2590.
43. FINTA C, ZAPHIROPOULOS PG: Intergenic mRNA molecules resulting from trans-splicing. J. Biol. Chem. (2002) 277(8):5882-5890.
44. BRUDNO M, GELFAND MS, SPENGLER S et al.: Computational analysis of candidate intron regulatory elements for tissue-specific alternative pre-mRNA splicing. Nucleic Acids Res. (2001) 29(11):2338-2348.
45. MAHENDROO MS, MENDELSON CR, SIMPSON ER: Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. J. Biol. Chem. (1993) 268(26):19463-19470.
46. SHOZU M, ZHAO Y, BULUN SE, SIMPSON ER: Multiple splicing events involved in regulation of human aromatase expression by a novel promoter, 1.6. Endocrinology (1998) 139(4):1610-1617.
47. CUI X, NELSON DR, STROBEL HW: A novel human cytochrome P450 4F isoform (CYP4F11): cDNA cloning, expression, and genomic structural characterization. Genomics (2000) 68(2):161-166.
48. DESROCHERS M, CHRISTOU M, JEFCOATE C, BELZIL A, ANDERSON A: New proteins in the rat CYP2B subfamily: presence in liver microsomes of the constitutive CYP2B3 protein and the phenobarbital-inducible protein product of alternatively spliced CYP2B2 mRNA. Biochem. Pharmacol. (1996) 52(8):1311-1319.
49. BLACK VH, WANG A, HENRY M, SHAW P: Molecular cloning of cDNA for guinea pig CYP1A2 comparison with guinea pig CYP1A1. Arch. Biochem. Biophys. (1997) 344(1):11-17.
50. GRAM TE, OKINE LK, GRAM RA: The metabolism of xenobiotics by certain extrahepatic organs and its relation to toxicity. Ann. Rev. Pharmacol. Toxicol. (1986) 26:259-291.
51. BOYD MR: Biochemical mechanisms in chemical-induced lung injury: roles of metabolic activation. Crit. Rev. Toxicol. (1980) 7(2):103-176.
52. GRABOWSKI PJ, BLACK DL: Alternative RNA splicing in the nervous system. Prog. Neurobiol. (2001) 65(3):289-308. Review on alternative splicing in the nervous system.
53. GONZALEZ FJ: Human cytochromes P450: problems and prospects. Trends Pharmacol. Sci. (1992) 13(9):346-352.
54. BROSEN K: Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin. Pharmacokinet. (1990) 18(3):220-239.
55. STROBEL HW, THOMPSON CM, ANTONOVIC L: Cytochromes P450 in brain: function and significance. Curr. Drug Metab. (2001) 2(2):199-214. Review of brain P450s.
56. MORTIMER O, PERSSON K, LADONA MG et al.: Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P450IID1. Clin. Pharmacol. Ther. (1990) 47(1):27-35.
57. SINDRUP SH, ARENDT-NIELSEN L, BROSEN K et al.: The effect of quinidine on the analgesic effect of codeine. Eur. J. Clin. Pharmacol. (1992) 42(6):587-591.
58. CHEN ZR, IRVINE RJ, BOCHNER F, SOMOGYI AA: Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia. Life Sci. (1990) 46(15):1067-1074.
59. SINDRUP SH, BROSEN K, BJERRING P et al.: Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin. Pharmacol. Ther. (1990) 48(6):686-693.
60. BROSEN K, SINDRUP SH, SKJELBO E, NIELSEN KK, GRAM LF: Role of genetic polymorphism in psychopharmacology - an update. Psychopharmacol. Ser. (1993) 10:199-211.
61. YU AM, IDLE JR, HERRAIZ T, KUPFER A, GONZALEZ FJ: Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics (2003) 13(6):307-319.
62. YU AM, IDLE JR, BYRD LG et al.: Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics (2003) 13(3):173-181.
63. FUNAE Y, KISHIMOTO W, CHO T, NIWA T, HIROI T: CYP2D in the brain. Drug Metab. Pharmacokinet. (2003) 18(6):337-349. Review on brain CYP2Ds.
64. ZHUGE J, YU YN: Three new alternative splicing variants of human cytochrome P450 2D6 mRNA in human extratumoral liver tissue. World J. Gastroenterol. (2004) 10(22):3356-3360.
65. WOO SI, HANSEN LA, YU X, MALLORY M, MASLIAH E: Alternative splicing patterns of CYP2D genes in human brain and neurodegenerative disorders. Neurology (1999) 53(7):1570-1572.
66. HUANG Z, FASCO MJ, KAMINSKY LS: Alternative splicing of CYP2D mRNA in human breast tissue. Arch. Biochem. Biophys. (1997) 343(1):101-108.
67. GAEDIGK A, GAEDIGK R, LEEDER JS: CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein? Biochem. Biophys. Res. Commun. (2005) 336(4):1241-1250. Details of all CYP2D splice variants with illustrative figure.
68. SCOTT EE, HE YQ, HALPERT JR: Substrate routes to the buried active site may vary among cytochromes P450: mutagenesis of the F-G region in P450 2B1. Chem. Res. Toxicol. (2002) 15(11):1407-1413.
69. GUENGERICH FP, HANNA IH, MARTIN MV, GILLAM EM: Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. Biochemistry (2003) 42(5):1245-1253.
70. WHITLOCK JP, JR.: Induction of cytochrome P4501A1. Ann. Rev. Pharmacol. Toxicol. (1999) 39:103-125.
71. BERESFORD AP: CYP1A1: friend or foe? Drug Metab. Rev. (1993) 25(4):503-517.
72. VASQUEZ HG, STROBEL H: Identification of cytochrome P450s in human glioma cell line. Int. J. Oncol. (1998) 12(6):1291-1294.
73. GENG J, STROBEL HW: Expression, induction and regulation of the cytochrome P450 monooxygenase system in the rat glioma C6 cell line. Brain Res. (1998) 784(1-2):276-283.
74. KOMMADDI RP, TURMAN CM, MOORTHY B et al.: An alternate spliced cytochrome P4501A1, a xenobiotic metabolizing enzyme, present in human brain does not bioactivate arylhydrocarbons to carcinogenic DNA binding metabolite(s). Manuscript submitted (2005).
75. GERVASINI G, CARRILLO JA, BENITEZ J: Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds. Clin. Pharmacokinet. (2004) 43(11):693-706.
76. NIWA T, HIROI T, TSUZUKI D et al.: Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res. Mol. Brain Res. (2004) 129(1-2):117-123.
77. LEE C, ATANELOV L, MODREK B, XING Y: ASAP: the Alternative Splicing Annotation Project. Nucleic Acids Res. (2003) 31(1):101-105. Computer program for identifying tissue-specific alternative mRNA transcripts for a given gene.
78. LEUNG YK, LAU KM, MOBLEY J, JIANG Z, HO SM: Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res. (2005) 65(9):3726-3734.
79. SCHWEIKL H, TAYLOR JA, KITAREEWAN S et al.: Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics (1993) 3(5):239-249.
80. MILES JS, MCLAREN AW, WOLF CR: Alternative splicing in the human cytochrome P450IIB6 gene generates a high level of aberrant messages. Nucleic Acids Res. (1989) 17(20):8241-8255.
81. LAMBA V, LAMBA J, YASUDA K et al.: Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J. Pharmacol. Exp. Ther. (2003) 307(3):906-922.
82. FINTA C, ZAPHIROPOULOS PG: The human CYP2C locus: a prototype for intergenic and exon repetition splicing events. Genomics (2000) 63(3):433-438.
83. WARNER SC, FINTA C, ZAPHIROPOULOS PG: Intergenic transcripts containing a novel human cytochrome P450 2C exon 1 spliced to sequences from the CYP2C9 gene. Mol. Biol. Evol. (2001) 18(10):1841-1848.
84. ZAPHIROPOULOS PG: Exon skipping and circular RNA formation in transcripts of the human cytochrome P450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis. Mol. Cell. Biol. (1997) 17(6):2985-2993.
85. HUANG Z, FASCO MJ, SPIVACK S, KAMINSKY LS: Comparisons of CYP2D messenger RNA splice variant profiles in human lung tumors and normal tissues. Cancer Res. (1997) 57(13):2589-2592.
86. YAMAKOSHI Y, KISHIMOTO T, SUGIMURA K, KAWASHIMA H: Human prostate CYP3A5: identification of a unique 5′-untranslated sequence and characterization of purified recombinant protein. Biochem. Biophys. Res. Commun. (1999) 260(3):676-681.
87. BUSI F, CRESTEIL T: CYP3A5 mRNA degradation by nonsense-mediated mRNA decay. Mol. Pharmacol. (2005) 68(3):808-815.
88. BUSI F, CRESTEIL T: Phenotyping-genoryping of alternatively spliced genes in one step: study of CYP3A5*3 polymorphism. Pharmacogenet. Genomics (2005) 15(6):433-439.
89. CHABRE O, PORTRAT-DOYEN S, CHAFFANJON P et al.: Bilateral laparoscopic adrenalectomy for congenital adrenal hyperplasia with severe hypertension, resulting from two novel mutations in splice donor sites of CYP11B1. J. Clin. Endocrinol. Metab. (2000) 85(11):4060-4068.
90. CHABRE O, PORTRAT-DOYEN S, VIVIER J, MOREL Y, DEFAYE G: Two novel mutations in splice donor sites of CYP11B1 in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. Endocr. Res. (2000) 26(4):797-801.
91. COSTA-SANTOS M, KATER CE, DIAS EP, AUCHUS RJ: Two intronic mutations cause 17-hydroxylase deficiency by disrupting splice acceptor sites: direct demonstration of aberrant splicing and absent enzyme activity by expression of the entire CYP17 gene in HEK-293 cells. J. Clin. Endocrinol. Metab. (2004) 89(1):43-48.
92. YAMAGUCHI H, NAKAZATO M, MIYAZATO M et al.: Identification of a novel splicing mutation and 1-bp deletion in the 17α-hydroxylase gene of Japanese patients with 17α-hydroxylase deficiency. Hum. Genet. (1998) 102(6):635-639.
93. MEANS GD, KILGORE MW, MAHENDROO MS, MENDELSON CR, SIMPSON ER: Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues. Mol. Endocrinol. (1991) 5(12):2005-2013.
94. SIMPSON ER, MAHENDROO MS, MEANS GD et al.: Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev. (1994) 15(3):342-355.
95. SEBASTIAN S, BULUN SE: A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the Human Genome Project. J. Clin. Endocrinol. Metab. (2001) 86(10):4600-4602.
96. HIGASHI Y, TANAE A, INOUE H, HIROMASA T, FUJII-KURIYAMA Y: Aberrant splicing and missense mutations cause steroid 21-hydroxylase [P450(C21)] deficiency in humans: possible gene conversion products. Proc. Natl. Acad. Sci. USA (1988) 85(20):7486-7490.
97. LEE HH, CHANG SF: Multiple transcripts of the CYP21 gene are generated by the mutation of the splicing donor site in intron 2 from GT to AT in 21-hydroxylase deficiency. J. Endocrinol. (2001) 171(3):397-402.
98. SCHULZE E, BETTENDORF M, MASER-GLUTH C, DECKER M, SCHWABE U: Allele-dropout using PCR-based diagnosis for the splicing mutation in intron-2 of the CYP21B-gene: successful amplification with a Taq/Pwo-polymerase mixture. Endocr. Res. (1998) 24(3-4):637-641.
99. REN S, NGUYEN L, WU S et al.: Alternative splicing of vitamin D-24-hydroxylase: a novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. J. Biol. Chem. (2005) 280(21):20604-20611.
100. GARUTI R, LELLIN, BAROZZINI M et al.: Cerebrotendinous xanthomatosis caused by two new mutations of the sterol-27-hydroxylase gene that disrupt mRNA splicing. J. Lipid Res. (1996) 37(7):1459-1467.
101. CHEN W, KUBOTA S, SEYAMA Y: Alternative pre-mRNA splicing of the sterol 27-hydroxylase gene (CYP 27) caused by a G to A mutation at the last nucleotide of exon 6 in a patient with cerebrotendinous xanthomatosis (CTX). J. Lipid Res. (1998) 39(3):509-517.
102. CHEN W, KUBOTA S, UJIKE H, ISHIHARA T, SEYAMA Y: A novel Arg362Ser mutation in the sterol 27-hydroxylase gene (CYP27): its effects on pre-mRNA splicing and enzyme activity. Biochemistry (1998) 37(43):15050-15056.
103. CHRISTMAS P, URSINO SR, FOX JW, SOBERMAN RJ: Expression of the CYP4F3 gene, tissue-specific splicing and alternative promoters generate high and low K(m) forms of leukotriene B(4) ζ-hydroxylase. J. Biol. Chem. (1999) 274(30):21191-21199.
104. SCHUG J, OVERTON GC: Transcription Element Search Software on the WWW. Technical Report (CBIL-TR-1997-1001-v0.0), Computational Biology and Informatics Laboratory University of Pennsylvania, School of Medicine (1998).
105. http://www.imm.ki.se/CYPalleles/ Home page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee (2001).